Provided by Tiger Trade Technology Pte. Ltd.

Anixa Biosciences

2.96
+0.21007.64%
Post-market: 3.010.0500+1.69%18:00 EST
Volume:132.51K
Turnover:386.39K
Market Cap:98.80M
PE:-8.79
High:3.00
Open:2.80
Low:2.77
Close:2.75
52wk High:5.46
52wk Low:2.33
Shares:33.38M
Float Shares:30.46M
Volume Ratio:0.69
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3367
EPS(LYR):-0.3367
ROE:-67.17%
ROA:-38.83%
PB:6.52
PE(LYR):-8.79

Loading ...

Company Profile

Company Name:
Anixa Biosciences
Exchange:
NASDAQ
Establishment Date:
1982
Employees:
4
Office Location:
3150 Almaden Expressway,Suite 250,San Jose,California,United States
Zip Code:
95118
Fax:
- -
Introduction:
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Directors

Name
Position
Amit Kumar
Director,Chairman of the Board and Chief Executive Officer
Arnold Baskies
Independent Director
Emily Gottschalk
Independent Director
Lewis H. Titterton
Lead Independent Director

Shareholders

Name
Position
Amit Kumar
Director,Chairman of the Board and Chief Executive Officer
Michael J. Catelani
President,Chief Operating Officer and Chief Financial Officer